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Transcriptional regulation is modulated in part by chromatin-
remodeling enzymes that control gene accessibility by altering
chromatin compaction or nucleosome positioning. Brahma-re-
latedgene1 (Brg1), a catalytic subunitof themammalianSWI/SNF
chromatin-remodeling enzymes, is required for both myoblast
proliferationanddifferentiation,andthecontrolofBrg1phosphor-
ylation by calcineurin, PKC1, and p38 regulates the transition to
differentiation.However,wehypothesized thatBrg1activitymight
be regulatedbyadditional kinases.Here,we report thatBrg1 is also
a target of casein kinase 2 (CK2), a serine/threonine kinase, in pro-
liferating myoblasts. We found that CK2 interacts with Brg1, and
mutation of putative phosphorylation sites to non-phosphorylat-
able (Ser to Ala, SA) or phosphomimetic residues (Ser to Glu, SE)
reduced Brg1 phosphorylation by CK2. Although BRG1-deleted
myoblasts that ectopically express the SA-Brg1 mutant prolifer-
ated similarly to the parental cells or cells ectopically expressing
wild-type (WT) Brg1, ectopic expression of the SE-Brg1 mutant
reduced proliferation and increased cell death, similar to observa-
tions from cells lacking Brg1. Moreover, pharmacological inhibi-
tion of CK2 increased myoblast proliferation. Furthermore, the
Pax7 promoter, which controls expression of a key transcription
factor required for myoblast proliferation, was in an inaccessible
chromatinstate in theSE-Brg1mutant, suggesting thathyperphos-
phorylated Brg1 cannot remodel chromatin. WT-, SA-, and SE-
Brg1exhibiteddistinctdifferences in interactingwithandaffecting
expression of the SWI/SNF subunits Baf155 and Baf170 and dis-
played differential sub-nuclear localization. Our results indicate
that CK2-mediated phosphorylation of Brg1 regulates myoblast
proliferationandprovides insight intoonemechanismbywhichcom-
positionof themammalianSWI/SNFenzymecomplex is regulated.
Chromatin-remodeling enzymes are large, multisubunit com-
plexes that hydrolyze ATP to disrupt histone/DNA contacts and
modify chromatin structure by increasing or decreasing its acces-
sibility to regulatory factors controlling transcription, replication,
recombination, and repair (1–3).ThemammalianSWI/SNFcom-
plexes are a family of chromatin-remodeling enzymes that consist
of one of two mutually exclusive ATPases called Brahma or
Brahma-relatedgene1 (Brg1) (4–6) andat least 11 additional sub-
units that are assembled in a seemingly limitless array of combina-
tions that is believed to confer context- and cell type-specific func-
tions (7, 8).
In addition to subunit composition dictating function,
emerging evidence demonstrates that subunits of the complex
are responsive to different signal pathways and undergo post-
translational modifications that influence function (9–13). For
instance, the Baf60c subunit is phosphorylated by the p38mito-
gen-activated protein kinase to allow the assembly of the rest of
the remodeling complex at myogenic promoters (10, 14). The
Brg1 ATPase is necessary for primary myoblast proliferation
and for skeletalmuscle differentiation (9, 15, 16).Our group has
recently shown that Brg1 is phosphorylated by protein kinase C
1 (PKC1), which represses Brg1 function and myogenesis
(9). We also found that calcineurin is the phosphatase that
opposes PKC1 phosphorylation of Brg1 to allow chromatin
remodeling and differentiation (9). Moreover, replacement of
endogenous Brg1 with the phosphomimetic Brg1 mutant
inhibited myogenesis, whereas replacement with a non-phos-
phorylatable mutant allowed myogenesis independently of cal-
cineurin signaling (9). In other systems, insulin signaling
induces phosphorylation of Baf60c in liver as a requisite step in
lipogenic gene activation (17), and the DPF/Baf45c subunit
becomes phosphorylated in cardiac muscle in response to
hypertrophic signaling (11). Changes in Brg1 phosphorylation
have been noted in ovarian tumors (18), whereas ataxia telan-
giectasia-mutated kinase phosphorylates Brg1 in response to
DNA-damage signaling (19). It therefore appears that the
mammalian SWI/SNF enzyme complexmay be a target ofmul-
tiple signal transduction pathways in a context-dependent
manner.
Mass spectrometry analysis of Brg1 in the presence and
absence of a calcineurin inhibitor not only identified phosphor-
ylated peptides dependent upon calcineurin but also additional
phosphopeptides that did not change due to calcineurin inhi-
bition (9), suggesting that other phosphatases and kinases also
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regulate Brg1 during myogenesis and almost certainly in other
cell types. Further analysis of Brg1 sequence with NetPhosK
predictor program (20) showed casein kinase 2 (CK2)2 as a
putative kinase for Brg1 (9). CK2 is a ubiquitously expressed
Ser/Thr kinase with over 300 identified substrates (21, 22). It is
expressed as a tetrameric complex consisting of two catalytic
subunits, CK2 or CK2, and a dimer of CK2 regulatory sub-
units (22). CK2 is implicated in cell survival, cell cycle, apopto-
sis, and transcriptional regulation. Mice lacking the  subunit
of CK2 develop cardiac and neural tube defects that lead to
death during embryogenesis; deletion of the  catalytic sub-
unit specifically impairs spermatogenesis (23, 24). Knock-out of
the  subunit causes post-implantation lethality, and condi-
tional knock-out indicates a requirement for CK2 in cell via-
bility (25). Similarly, in cultured cells, inhibition of CK2 leads to
blockage of cell cycle progression and death (26–28). Here, we
explore a possible role for CK2 in regulation of Brg1 during
skeletal muscle proliferation and differentiation.
The ability of skeletal muscle to grow and to regenerate in
response to injury relies on the resident stem cell population,
termed satellite cells. Satellite cells are located under the basal
lamina surrounding the myofibers (29). Under homeostatic
conditions, satellite cells have a slow rate of turnover and are
maintained in a non-proliferative state (30–32). To preserve
the functional satellite cell pool, fine-tuned regulation of tran-
scription must exist. Relevant for the myogenic lineage is Pax7,
a transcriptional regulator required for proliferation of the
muscle satellite cell pool (31–35). Deletion of Pax7 in mice
leads to death within 2–3 weeks after birth due to failure of
developing neural crest derivatives (36). Pax7 knock-out mice
have a reduced satellite cell pool, a progressive loss of the exist-
ing satellite cell pool, and impaired capabilities to regenerate
muscle (37–39). Our group recently showed that Pax7 is a tar-
get gene of Brg1 in proliferating myoblasts (15). Brg1 binds to
the Pax7 promoter, locally remodels chromatin, and enhances
Pax7 expression. Reintroduction of Pax7 into primary myo-
blasts lacking Brg1 rescues the cells from apoptosis and almost
completely restores proliferation (15). These data support a
mechanism whereby Brg1 regulates Pax7 to promote cell sur-
vival and proliferation. In this work, we present new evidence
that CK2-dependent phosphorylation affects Brg1 chromatin
remodeling activity and, consequently, the transcription of
Pax7. We describe a novel mechanism by which CK2 regulates
Brg1-dependent myoblast proliferation by influencing the sub-
unit composition of the SWI/SNF complex, its sub-nuclear
localization, and its chromatin remodeling properties at the
Pax7 promoter. Our results suggest that regulation of the phos-
phorylation state of Brg1 contributes to the regulation of sub-
unit composition of the mammalian SWI/SNF complex. We
hypothesize that determination of the myoblast fate requires a
dynamic equilibrium between phosphorylation and dephos-
phorylation of the chromatin-remodeling enzyme. Moreover,
this work further supports the concept that the mammalian
SWI/SNF complex acts as an integrator for multiple signaling
pathways to regulate myogenesis.
Results
Brg1 is phosphorylated by CK2 in vitro
Our group has shown that the regulation of Brg1 phosphor-
ylation by PKC1 and the phosphatase, calcineurin, controls
the ability of Brg1 to promote differentiation of cultured pri-
mary and immortalized myoblasts (9). In the course of that
work, analysis of putative phosphorylation sites in Brg1 sug-
gested that CK2 might phosphorylate Brg1 (9). Sequence anal-
ysis using the NetphosK program for predicting kinase sites (9,
20) showed 10 potential phosphorylation sites for CK2 in the
murine Brg1-coding region that are conserved in the human
sequence (Fig. 1A). To investigate whether Brg1 could be phos-
phorylated by CK2 in vitro, wemutated these 10 serine residues
to non-phosphorylatable alanine (SA-Brg1) or phosphomi-
metic glutamate (SE-Brg1).Wild type (WT-), SA-, and SE-Brg1
were expressed via an in vitro transcription/translation proto-
col and purified by immunoprecipitation (Fig. 1B) with a poly-
clonal rabbit antisera against Brg1 (40). Purified Brg1 proteins
were tested for phosphorylation in the presence or absence of
purifiedCK2.AutoradiogramsshowedthatWT-Brg1wasphos-
phorylated by CK2 (Fig. 1B). CK2-dependent phosphorylation
of the SA- and SE-Brg1mutants was quantified and normalized
to the phosphorylation intensity of WT-Brg1 (Fig. 1, B and C).
A 50% decrease in the phosphorylation of mutant SA- or SE-
Brg1 was detected (Fig. 1C). The remaining phosphorylation
indicates the presence of other unidentified CK2 target resi-
dues. To further characterize the Brg1 phosphorylation that
was observed, we expressed and purified glutathione S-trans-
ferase (GST)-Brg1 fusions spanning the N to C termini of Brg1
(Fig. 1D) (9). The fragment that contains the BRKdomain (frag-
ment 2) and the C-terminal fragments (fragments 4–6) that
flank or contain the bromodomain were phosphorylated by
CK2 in vitro (Fig. 1E). Phosphorylation of fragment 5 indicates
the presence of unidentified target amino acids. Fragment 6
was heavily phosphorylated, suggesting CK2 phosphorylation
occurs predominantly at the C-terminal end of Brg1. A repre-
sentative Coomassie Brilliant Blue-stained gel shows the purity
of the purifiedGST-Brg1 fragments and is included as a loading
control (Fig. 1E).
Given our prior interest in the consequences of Brg1 phos-
phorylation during skeletal muscle differentiation, we used cul-
tured proliferating primary myoblasts derived frommouse sat-
ellite cells to extend our investigation. We first characterized
the expression of CK2 subunits in proliferating and differenti-
ating myoblasts. mRNA (Fig. 2A) and protein levels (Fig. 2B) of
the CK2, , and  subunits were largely unchanged. Consid-
ering that Brg1 was phosphorylated by CK2 in vitro, we asked
whether an interaction between the two proteins might oc-
cur in cells. Reciprocal co-immunoprecipitation experiments
showed an interaction between CK2 and Brg1 in proliferating
primary myoblasts (Fig. 2C). These results indicate that Brg1
and CK2 can interact in proliferating myoblasts and suggest
2 The abbreviations used are: CK2, casein kinase 2; TBB, 4,5,6,7-tetrabromo-
benzotriazole; Baf, BRG1- and Brahma-associated factors; MHC II, myosin
heavy chain II; REAA, restriction enzyme accessibility assay; FRAP, fluores-
cence recovery after photobleaching; ESC, embryonic stem cell; GM,
growthmedium; RNA pol II, RNA polymerase II; HBSS, Hanks’ balanced salt
solution.
CK2-dependent phosphorylation regulates Brg1 activity
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that CK2-mediated phosphorylation of Brg1 may occur via
interaction of the two proteins.
Phosphomimetic mutation of putative CK2 sites in Brg1
inhibits primarymyoblast proliferation and leads to cell death,
whereas CK2 inhibition increasesmyoblast proliferation
To assess the functionality of CK2-mediated phosphoryla-
tion of Brg1, we utilized a system we previously described to
replace endogenous Brg1 with a wild type or mutated version
(9). Briefly, satellite cells were isolated from skeletal muscle
tissue ofmice homozygous for a conditional allele encoding the
Brg1 protein (Brg1 c/c) (41) and propagated in culture. The
proliferating myoblasts were infected with adenovirus encod-
ing the Cre recombinase (Ad-Cre) or an empty vector as a neg-
ative control; retroviruses encoding the described yellow fluo-
rescent protein (YFP)-labeled WT-SA- or SE-Brg1 mutations
were also introduced. The YFP-Brg1 was positioned upstream
of an mCherry-coding sequence flanked by Cre recombinase
sites. Therefore, in the absence ofAd-Cre, the endogenousBrg1
was retained, and mCherry, but not YFP-Brg1, was expressed
from the retrovirus. In the presence of Ad-Cre, the endogenous
Brg1 was deleted, and the exogenous YFP-Brg1 was expressed.
We first evaluated cell proliferation via cell counting. All cells
infected with empty adenovirus and retrovirus encoding YFP-
tagged Brg1 proteins proliferated with similar kinetics (endog-
enous Brg1 expressed, exogenous Brg1 not expressed; gray
lines, Fig. 3A). We previously demonstrated that deletion of
Brg1 in primary myoblasts resulted in inhibition of prolifera-
tion and cell death and that exogenous expression of wild-type
Brg1 rescued the viability and proliferation phenotypes (15).
Consistent with these prior results, Ad-Cre-treated cells ectop-
ically expressing WT-Brg1 showed growth kinetics similar to
the untreated controls (Fig. 3A). Substitution of the 10 putative
CK2 phosphorylation sites in Brg1 with alanine (SA-Brg1) res-
cued cell viability and proliferation similar to that observed in
WT-Brg1-expressing cells. In contrast, the phosphomimetic
mutant, SE-Brg1, showed an inhibition of proliferation and a
subsequent loss of cell number (Fig. 3A). The phenotype of the
SE-Brg1-expressing cells mirrored that of primary myoblasts
deleted for Brg1 (15). The results suggest that phosphorylation
of Brg1 by CK2 negatively impacts myoblast proliferation and
viability. Expression of the exogenous WT-, SA-, and SE-Brg1
upon Ad-Cre infection was verified byWestern blotting, which
is evident by the increase in the molecular weight of the YFP-
tagged Brg1 constructs compared with the endogenous Brg1
(Fig. 3B). The SE-Brg1-expressing cells showed a decrease in
expression of the transcription factor Pax7, which is required
for myoblast proliferation (15, 31–39, 42), and an increase in
activated caspase 3 expression, which indicates apoptosis (Fig.
3B) (15, 43). These results at least partially explain the prolifer-
ation defect and loss of viability of the SE-Brg1mutant. Nuclear
Figure 1. Brg1 is phosphorylated in vitrobyCK2.A, schematic representationof the locationof theputative sites for CK2phosphorylation identifiedbyNetphosK
(9, 20). B, representative autoradiograms of in vitro CK2-treated WT-, SA-, and SE-Brg1 (top). A representative Western blot detecting Brg1 is shown for comparison
(bottom). EV, empty vector. C, Brg1 labeling was quantified by normalizing autoradiography signals to theWestern blotting for Brg1. Data represent the average of
three independent experiments S.D.; *, p 0.01. Phosphorylation in the WT-Brg1-expressing cells was set at 1. A.U., arbitrary units. D, diagram of the GST-Brg1
fragments (#1–6)usedtocharacterizethephosphorylationbyCK2relativetothepredictedCK2sitesandtheknowndomainsofBrg1.E, representativeautoradiogram
of in vitroCK2-labeledGST-Brg1 fragments (top). Representative Coomassie Brilliant Blue (CBB) staining is shown for comparison (bottom).
CK2-dependent phosphorylation regulates Brg1 activity
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Figure 3. Phosphomimetic mutations in Brg1 inhibit proliferation and reduce viability of primary myoblasts. A, proliferation assay of Brg1-deficient
(Brg1 c/c) cells transducedwithWT-, SA-, or SE-Brg1. Data represent the average of three independent experiments S.D. B, representativeWestern blots (WB)
showing the expression of Brg1, Pax7, activated caspase 3, and PI3K as a loading control. C, representative confocal microscopy images showing nuclear
localization of WT-, SA-, and SE-Brg1 expressed in proliferating primary myoblasts. D, representative confocal microscopy images of primary myoblasts
transducedwith theWT-, SA-, and SE-Brg1mutants thatweredifferentiated for 48h and immunostained for Brg1 andMyoD. E, representative lightmicroscopy
images of the phenotypes observed when myoblasts expressing the indicated Brg1 protein were differentiated for 48 h; cells were immunostained using an
anti-myosin heavy chain II (MHCII) antibody.
Figure 2. Brg1 and CK2 interact in primary myoblasts. Gene (A) and protein (B) expression of CK2, CK2, and CK2 do not change over the course of
differentiation of primary myoblasts. Expression in proliferating (P) primary myoblasts was set at 1. Data represent the average of three independent experi-
ments, each assayed in triplicate S.D. Observed differences were not statistically significant. MHC II levels are shown as a differentiation control, and PI3K
levels are shown as a loading control for theWestern blots (WB). C, Brg1 and CK2 interact in proliferating primary myoblasts. A representative Western blot of
the reciprocal immunoprecipitations (IP)of Brg1 and CK2 is shown. Pulldown with IgG was used as a negative control.
CK2-dependent phosphorylation regulates Brg1 activity
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localization of Brg1 wild-type and mutant forms was verified
by confocal microscopy, although the SE-Brg1 mutant also
showed some cytoplasmic staining (Fig. 3C).
To assess a role for CK2-dependent phosphorylation of Brg1
in myogenesis, we induced the primary myoblasts to differen-
tiate. Cells expressing the WT-Brg1 and the SA-Brg1 mutant
expressedMyoD (Fig. 3D) and differentiated, as shown bymyo-
tube formation and expression of the differentiation marker
myosin heavy chain II (MHCII, Fig. 3E). Cells expressing the
SE-Brg1 mutant showed limited expression of the myogenic
regulatory factor MyoD and the differentiation marker MHCII
and were unable to differentiate. Failure of the SE-Brg1 mutant
cells to differentiate likely can be attributed to the fact that cells
were undergoing apoptosis.
Because mimicking the effect of CK2 kinase activity on Brg1
reduced myoblast proliferation, inhibition of CK2 might be
expected to increase myoblast proliferation. However, CK2 has
many target proteins; attempts to knock down CK2 by RNA
inhibition have largely resulted in growth inhibition and cell
death (21, 22). Therefore, we investigated the effect of 4,5,6,7-
tetrabromobenzotriazole (TBB), a highly specific inhibitor of
the ATP-binding site in CK2 (44), on CK2-mediated phosphor-
ylation of Brg1 and on myoblast proliferation and viability. In
vitro transcribed/translated Brg1 was mixed with CK2 enzyme
in vitro, and increasing amounts of TBB were added to the
reaction. Inhibition of Brg1 phosphorylation was observed at 5
and 10 M TBB (Fig. 4, A and B). Proliferating myoblasts
derived from C57Bl/6 satellite cells were incubated with
increasing concentrations of TBB for 4 days, and the prolifera-
tion rate was evaluated. Fig. 4C shows an increase in the prolif-
eration of myoblasts when treated with sub-lethal concentra-
tions of TBB (1–10 M). Consistent with other cell types, TBB
was toxic to the myoblasts at concentrations above 50 M (44,
45). Brg1 expression was not affected by TBB treatment (Fig.
4D). Overall, these results suggest that a functional conse-
quence of phosphorylation of Brg1 by CK2 is to regulate myo-
blast proliferation.
Phosphomimetic mutation of putative CK2 sites in Brg1
inhibits proliferation and viability by preventing chromatin
remodeling at and expression from the Pax7 promoter
We previously showed that Brg1 regulates chromatin acces-
sibility at and expression from the promoter of the transcrip-
tional regulator Pax7, which is necessary for satellite cell pro-
liferation and survival under non-differentiating conditions
(15, 31–39, 42). To better understand the effect of CK2 phos-
phorylation of Brg1, we examined Pax7 expression in Brg1-
deficient cells expressing WT-Brg1, SA-Brg1, or SE-Brg1. We
observed a decrease in Pax7 protein expression in proliferating
SE-Brg1- but not in the SA-Brg1-expressing myoblasts com-
pared with the WT control (Fig. 3B). Consistent with these
results, Pax7mRNA levels were decreased in SE-Brg1-express-
ing cells, indicating a deficiency at the level of transcription (Fig.
5A). We then analyzed whether or not this phenotype was due
to mechanistic deficiencies in the chromatin-binding or chro-
matin-remodeling properties of the phosphomimetic Brg1.
Chromatin immunoprecipitation (ChIP) assays revealed bind-
ing of Brg1 to the Pax7 promoter region relative to the IgG
control in proliferating myoblasts expressing WT-Brg1 or SA-
Brg1 (Fig. 5,B andC). ChIP results also indicated thatmyoblasts
expressing SE-Brg1 showed little or no binding of Brg1 to the
Pax7 promoter, matching levels observed in cells deleted for
Figure 4. Inhibitionof CK2affects CK2-mediated in vitrophosphorylationof Brg1 andprimarymyoblast proliferation.A,dose-dependent inhibition of
CK2-mediated in vitro phosphorylation of Brg1 by TBB. Representative autoradiograms (top) and Western blots (WB) confirming the expression of Brg1
(bottom) are shown. B, quantification of phosphorylation changes presented as the mean  S.D. from four independent experiments *, p  0.0002. C,
proliferation assay of C57Bl/6 myoblasts treated with increasing concentrations of the CK2 inhibitor TBB. Data represent the average of three independent
experiments S.D. *, p 0.01. D, representative Western blots of Brg1 expression in primary myoblasts. PI3K was examined as a loading control.
CK2-dependent phosphorylation regulates Brg1 activity
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Brg1 and levels observed at the IgH enhancer, whichwas used as
a negative control sequence (Fig. 5, B and C). These results
suggest that the interaction between Brg1 and the Pax7 pro-
moter can be blocked by CK2-mediated hyperphosphorylation
of Brg1. The lack of SE-Brg1 binding to the Pax7 promoter
suggests a deficiency in chromatin remodeling at the promoter,
as we have previously demonstrated that Brg1 contributes sig-
nificantly to Pax7 promoter accessibility in proliferating myo-
blasts (15). Restriction enzyme accessibility assays (REAA) uti-
lizing two PvuII cleavage sites within the Pax7 promoter region
(Fig. 5D) showed a significant increase in the accessibility at two
nuclease sites in the promoter region of Pax7 that are 347 and
637 bp upstream of the transcription start site in the WT- and
SA-Brg1-expressing cells (primer sets 1 and 2, Fig. 5E). As
expected, deletion of Brg1 in the conditional myoblasts led to a
significant decrease in nuclease accessibility at the Pax7 pro-
moter, and accessibility in the presence of SE-Brg1 was simi-
larly inhibited (Fig. 5E). No PvuII cleavage was detected at the
restriction site located 6 kb upstream from the Pax7 promoter
or at a site within the coding sequence (primer sets 3 and 4, Fig.
5F) in each of the cells, reflecting inaccessibility to this nuclease
in these regions. Together, these results suggest that the
hyperphosphorylated state of Brg1 abolishes its binding to the
Pax7 promoter, reducing its capability for chromatin remodel-
ing, and therefore reducing Pax7 gene and protein expression
and leading to a loss of myoblast viability.
Intra-nuclearmobility and localization of Brg1 is altered in the
SA- and SE-Brg1mutants
Because the hyper-phosphorylated version of Brg1 was not
able to remodel chromatin at the Pax7 promoter, and thus
caused deficient proliferation and increased apoptosis, we
tested whether this protein has altered localization within the
nucleus and reduced binding to chromatin and/or the nuclear
matrix. First, taking advantage of the YFP labeling of the exog-
enous WT-, SA-, and SE-Brg1 alleles, we performed fluores-
cence recovery after photobleaching (FRAP). After photo-
bleaching a region of interest (3 m diameter) in the nucleus,
we observed half-time recoveries on the order of 15–25 s (Fig. 6,
A and B). FRAP measures binding and diffusion (46), and
because diffusion-limited recovery is very fast, on the order of
tenths of seconds (47), we were measuring binding in these
experiments. The initial recovery of fluorescence was faster for
themyoblasts expressing the SE-Brg1 construct comparedwith
the WT-Brg1, whereas the immobile fraction was smaller (Fig.
6, A and B). The initial recovery rate measures the binding that
is in more rapid equilibrium, whereas the immobile fraction
measures tight binding that did not recover during the 140-s
time course of the experiment. Thus, there are at least twopools
of BRG1, differing in binding constants and both affected by the
phosphomimetic mutation. These results suggest that the
phosphomimetic Brg1 mutant has increased mobility com-
pared with the wild-type and non-phosphorylatable Brg1.
Surprisingly, theSA-Brg1molecule,whichcannotbephosphor-
ylated, showed different binding properties compared with the
SE- and WT-Brg1 proteins. The initial recovery rate half-time
was similar to that of the SE-Brg1 protein, but the immobile
fraction was similar to that of theWT-Brg1 protein, suggesting
that despite the ability of the SA mutant to support chromatin
remodeling and expression at the Pax7 promoter and myo-
blast proliferation, the alteration in phosphorylatable serines
changed its physical properties and its binding properties in live
cells.
Nuclear fractionation experiments have shown that mam-
malian SWI/SNF proteins are associated with the nuclear
Figure5. Phosphomimetic Brg1mutantdoesnotbind toor remodel chromatin at thePax7promotor.A,mRNAexpression levels of Pax7 in the indicated
primary myoblasts. Values for the C57Bl/6 primary myoblasts were set at 1. B and C, quantification of ChIP assays measuring binding of Brg1 to the Pax7
promoter (B) or the IgH enhancer (C) in each of the indicated primary myoblasts. D, schematic representation of the location of the PvuII sites and the primer
sets used for REAA. E and F, quantification of REAAs performed on the indicated primarymyoblasts using primer sets 1 and 2 (E) or primer sets 3 and 4 (F). The
accessibility at the PvuII site assessed by primer set 1 in the WT-Brg1-expressing primary myoblasts was set at 1. All data represent the average of three
independent experiments, each assayed in triplicate S.D.; *, p 0.01.
CK2-dependent phosphorylation regulates Brg1 activity
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matrix, also called the nuclear scaffold or the nucleoskeleton
(48, 49). The nuclear matrix is the non-chromatin, fibrogranu-
lar ribonucleoprotein network that exists in the nucleus (50)
and serves to organize chromatin loops by providing an anchor-
ing point at the base of the loop (51). Because both the phos-
phomimetic and the non-phosphorylatable Brg1 mutants
exhibited altered nuclear mobility, we hypothesized that the
intra-nuclear distribution of the mutant proteins might be
affected. To test this hypothesis, we performed a sequential
nuclear extraction procedure that previously revealed the asso-
ciation of Brg1 with the nuclear matrix (48, 52). This fraction-
ation begins with the extraction of cytoplasmic proteins with
Triton X-100. Chromatin proteins then were released by
DNase I digestion. Samples were washed with high salt buffer,
Figure 6. Phosphomimetic and non-phosphorylatable mutations in Brg1 or inhibition of CK2 affects intranuclear mobility and association with
chromatin and the nuclear matrix. A, time course of representative confocal microscopy images from FRAP experiments performed on primary myoblasts
expressing WT-, SA-, or SE-Brg1. B, quantification of the fluorescence recovery of WT-, SA-, and SE-Brg1 mutants. Data represent the average values from five
independently examined cells S.E. n.d., not detected. C, representative Western blottings (WB) of Brg1 in the indicated fractions derived from proliferating
primary myoblasts. D, representative Western blottings from C57Bl/6 myoblasts for marker proteins to demonstrate the purity of the fractions used in C. E,
representative Western blots of Brg1 and marker proteins present in the indicated fractions from primary myoblasts treated with TBB.
CK2-dependent phosphorylation regulates Brg1 activity
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leaving a fraction containing the nuclear matrix proteins and
nuclear matrix-associated proteins. Fig. 6C shows a represen-
tative Western blot of the four fractions obtained for all the
primary myoblasts used. Parental primary myoblasts showed
endogenous Brg1 localized to the chromatin and to the nuclear
matrix in roughly equal proportions, a result also observed in
Brg1-deleted myoblasts ectopically expressing WT-Brg1 (Fig.
6C) and in other cell types (48, 52). The SE-Brg1 mutant was
found in the high-salt wash fraction (Fig. 6C), associated with
neither chromatin nor with the nuclear matrix, likely explain-
ing its inability to bind to the Pax7 promoter. Interestingly, the
SA-Brg1 mutation protein was exclusively found in the nuclear
matrix fraction (Fig. 6C). This result is consistent with the
FRAP data showing that the immobile fraction of the SA-Brg1
mutant was similar to that of WT-Brg1. The lack of a chroma-
tin-associated fraction may relate to the difference in initial
recovery half-time relative to the WT-Brg1. Additional
thoughts on how the SA-Brg1 mutant functions like the WT-
Brg1 in promoting Pax7 expression, despite not being associ-
ated with the soluble chromatin fraction, are presented under
the “Discussion.” Representative control Western blottings
show the purity of the fractions (Fig. 6D). Lamin 1 is only
localized to the nuclear matrix, RNA pol II is associated with
the chromatin and the nuclear matrix, and GAPDH is located
only in the cytosolic fraction.
To complement these results, we examined sub-nuclear
localization of Brg1 from cells treated with the CK2 inhibitor
TBB.TBB treatment reduced the level of Brg1 in the chromatin,
but not the nuclearmatrix fraction (Fig. 6E), consistentwith the
depletion of Brg1 in the chromatin fraction when the non-
phosphorylatable SA-Brg1 mutant was expressed (Fig. 6C).
TBB treatment also increased the gel mobility of chromatin-
associated Brg1, as would be expected if phosphates were
removed from a phosphoprotein (Fig. 6E). Interestingly, the gel
mobility of the nuclear matrix-associated Brg1 is equivalent to
that of the TBB-treated, chromatin-associated Brg1, suggesting
that the nuclear matrix-associated Brg1 is also relatively less
phosphorylated than the chromatin-associated Brg1. The
reduced phosphorylation state likely links with the ability of
Brg1 to promote Pax7 transcription (see “Discussion”). We
noted similar changes in gel mobility for RNA pol II; the chro-
matin-associated RNA pol II present in TBB-treated cells
showed increased gelmobility, similar to the increasedmobility
observed for RNA pol II in the nuclear matrix, with or without
TBB treatment. Prior reports indicate that CK2 interacts with
and phosphorylates RNApol II (53–56). Collectively, these data
suggest that CK2-dependent phosphorylation of Brg1 deter-
mines the sub-nuclear localization of this chromatin-remodel-
ing enzyme and specifically its association with chromatin and
the nuclear matrix.
Mutation of Brg1 alters association with other subunits of the
mammalian SWI/SNF complex
We asked then whether or not the association of Brg1 with
other members of the enzyme complex might be dependent in
the phosphorylation state of Brg1. The Baf170 and Baf155 sub-
units show greater than 60% identity (57) and are preferentially
incorporated into SWI/SNF complexes in certain cell types (7,
8). Specifically, mouse embryonic stem cells (ESCs) predomi-
nantly incorporate Baf155 into enzyme complexes (58). Upon
neuronal differentiation, Baf170 expression is induced,whereas
Baf155 expression decreases, and there is an increase in the
amount of SWI/SNF complexes that incorporate Baf170 (58).
We therefore investigated whether Baf170 and Baf155 associa-
tion with Brg1 was affected by the SA or SE mutations.
First, we analyzed whether the expression of SA- or SE-Brg1
had an effect on Baf155/Baf170 protein levels. Parental and
WT-Brg1-expressing myoblasts expressed Baf170 protein at
roughly equivalent levels. Baf170 levels were significantly
reduced in Brg1-deleted cells as well as in the SE-Brg1-express-
ing cells, although the SA-Brg1-expressing cells showed an
approximate 2-fold reduction (Fig. 7A). In contrast, Baf155 lev-
els were only modestly reduced in the SE-Brg1-expressing cells
(30% reduction) and in the Brg1-deleted cells (50% reduction),
although the SA-Brg1-expressing cells showed a greater than
3-fold increase in Baf155 levels (Fig. 7A). Reciprocal immuno-
precipitations showed that the Brg1 isolated from parental and
WT-Brg1-expressing myoblasts preferentially interacted with
Baf170, whereas the non-phosphorylatable SA-Brg1 mutant
preferentially interacted with Baf155 (Fig. 7B), which is consis-
tent with the levels of expression of these proteins. To further
analyze subunit association, we analyzed the binding of Baf170
and Baf155 to the Pax7 promoter by ChIP. Consistent with the
immunoprecipitation results, Baf170 can be localized at the
Pax7 promoter in parental andWT-Brg1-expressing cells (Fig.
7, C andD), whereas Baf155 only associates with the Pax7 pro-
moter in SA-Brg1-expressing cells (Fig. 7, E and F). The results
indicate that Brg1 normally associates with Baf170 in prolifer-
ating myoblasts; the non-phosphorylatable Brg1 switches to
associate with Baf155, and the phosphomimetic SE-Brg1 inter-
acts poorly with either Baf170 or Baf155.
Treatmentwith theCK2 inhibitor TBB provided corroborat-
ing results. TBB treatment inhibited Baf170 expression and
modestly increased Baf155 expression (Fig. 7G). Immunopre-
cipitation of Baf155 from cells treated with TBB showed an
increased level of Brg1 associated with Baf155 compared with
the association in untreated cells, whereas immunoprecipita-
tion of Baf170 from TBB-treated cells showed decreased asso-
ciation of Brg1 with Baf170 compared with the untreated cells
(Fig. 7H). Thus CK2 inhibition decreased interaction between
Brg1 and Baf170 while favoring the association of Brg1 with
Baf155.
Modification of amino acids in Brg1 that are targets for phos-
phorylation could affect interaction with other SWI/SNF sub-
units by directly altering the affinity of or the potential for
protein–protein interactions. Alternatively, the effect could be
more indirect. To gain insight into this question, we examined
Baf170 and Baf155 mRNA levels in control and Brg1-deleted
cells expressingWT, SA-, or SE-Brg1. Baf170mRNA levels (Fig.
7I) largely matched Baf170 protein levels (Fig. 7A). We note
that WT-Brg1-expressing cells showed higher levels of Baf170
mRNA than the parental cells expressing endogenous Brg1, but
this increase did not translate to significantly increased Baf170
protein levels (Fig. 7, I and A). Similarly, the Baf155 mRNA
levels in each of the different cells largely matched the Baf155
protein levels.Notably, the increase inBaf155 protein levelswas
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mirrored by an increase inBaf155mRNA (Fig. 7, J andA). These
data suggest that the preferential association between the SA-
Brg1 mutant and Baf155 in cells treated with the CK2 inhibitor
may be a result of changes in the expression of the genes that
encode Baf155 and Baf170, which then alters the relative avail-
ability of these subunits for SWI/SNF complex assembly. The
data do not exclude an effect of phosphorylation on protein–
protein interactions; instead, the findings suggest that associa-
tion of different SWI/SNF subunits may be regulated by multi-
ple mechanisms.
Discussion
Brg1 is an in vitro substrate for CK2
In silico analysis of the Brg1 protein sequence showed 10
residuesthatarepotential targetsforCK2-dependentphosphor-
ylation (Fig. 1A). CK2 phosphorylates Ser and Thr residues that
are in proximity to acidic residues (i.e. Ser-Xaa-Xaa-acidic,
where the acidic residue may be Glu, Asp, phospho-Ser, or
phospho-Tyr). There are constraints associated with using this
consensus sequence for the identification of CK2 targets, as the
presence of this sequence does not guarantee phosphorylation,
and there may be other determinants within the sequence that
modulate phosphorylation efficiency (22, 59). It is also possible
that certain sequences do not fit in this consensus sequence but
are effectively phosphorylated by CK2, as in the case of the
tumor suppressor p53 (60). In vitro phosphorylation experi-
ments using purified Brg1 confirmed that this ATPase is a sub-
strate of CK2. Purified Brg1 containing non-phosphorylatable
and phosphomimeticmutations at the identified potential CK2
sites showed decreased phosphorylation by CK2. This partial
decrease in phosphorylation is likely due to the presence of
other unidentified CK2 target residues elsewhere in the Brg1-
coding sequence. Our experiments with GST-Brg1 constructs
(Fig. 1E) showed that the fragment flanking the bromodomain
(construct 6) appeared to be heavily phosphorylated compared
with other fragments. Whether this indicates additional CK2
Figure 7. Inhibition of CK2 or expression of phosphomimetic or non-phosphorylatable Brg1mutations determines interactionwith Baf170 or Baf155.A,
representativeWestern blots (WB) showing 12%of the input for the subsequent immunoprecipitation (IP) experiments, which documents expression of Baf170 and
Baf155 in the indicated proliferating primary myoblasts. Bands were quantified using ImageJ. Brg1 expression was normalized to PI3K expression, and the value of
expression in the C57Bl/6myoblasts was set at 1. Relative expression levels are indicated below each band. B, representative profiles of Baf170 and Baf155 immuno-
precipitations of Brg1 from the indicatedprimarymyoblasts.C andD,ChIP experiments showingBaf170 recruitment to the Pax7promoter (C) or to the IgH enhancer
(D) when endogenous orWT-Brg1 is expressed. E and F,ChIP experiments showing Baf155 recruitment to the Pax7promoter (E) or to the IgH enhancer (F) when the
non-phosphorylatable Brg1mutant is expressed. Data in C–F represent the average of three independent experiments, each assayed in triplicate S.D.; *, p 0.01.
G, representativeWestern blottings showing the expression of Baf170, Baf15, and Brg1 in C57Bl/6 primarymyoblasts treatedwith increasing concentrations of TBB.
PI3K levelsweremeasuredasacontrol.H, representative immunoprecipitationsofBaf155/Brg1andBaf170/Brg1fromprimarymyoblasts treatedwith10MTBB. Iand
J, relative levelsofBaf170andBaf155mRNApresent in the indicatedmyoblasts. Levels inC57Bl6primarymyoblastswerenormalized to1.Data represent theaverage
of three independent experiments, each assayed in triplicate S.D.; *, p 0.01.
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18600 J. Biol. Chem. (2017) 292(45) 18592–18607
 at U
niversity of M
assachusetts M
edical Center/The Lam
ar Soutter Library on D
ecem
ber 8, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
sites in this region or simply reflects a strong preference for the
predicted sites that are present remains unclear. The results
also reflect the activity of purified CK2 on recombinant Brg1.
Additional differences in phosphorylation may exist due to the
incorporation of Brg1 into the SWI/SNF enzyme complex.
The argument for CK2 as a relevant kinase for the mamma-
lian SWI/SNF enzyme is supported by recent evidence showing
that CK2 phosphorylates DPF3a, an isoform of a different sub-
unit of the enzyme complex that is also called Baf45c (11). Upon
signaling that induces cardiac muscle hypertrophy, CK2 phos-
phorylates DPF3a at a specific serine residue. The consequence
is that phosphorylatedDPF3a and other SWI/SNF enzyme sub-
units bind to chromatin at promoters encoding fetal cardiac
genes that are silenced by the Hey family of transcriptional
repressors, resulting in displacement of Hey factors and re-
placement with transcriptional activators. Phosphorylation of
DPF3a was required for the interaction with theHey repressors
(11), suggesting a role for CK2-dependent phosphorylation of
mammalian SWI/SNF subunits. CK2 has also been implicated
as a regulator of other chromatin-remodeling enzymes. The
Drosophila Mi-2 ATPase is phosphorylated by CK2, which
increases both affinity for chromatin and in vitro enzymatic
activity (61).
CK2 is implicated as a kinase thatmodulates the ability of
Brg1 to support myoblast proliferation via induction of Pax7
expression
Mutations of Brg1 that mimic the constitutive phosphoryla-
tion of these 10 residues altered the proliferation and survival of
proliferating primary myoblasts. Cells expressing the SE-Brg1
mutant had a proliferation defect and underwent apoptosis, as
indicated by the induction of caspase 3 (Fig. 3B), similar to what
was observed in myoblasts deleted for Brg1 or myoblasts
expressing aBrg1 catalytically inactivemutant (15). Thus,mim-
icking constitutive phosphorylation of Brg1 at the implicated
sites renders Brg1 non-functional for its roles in promoting
myoblast cell division and viability and identifies at least some
of these residues as having a specific role in the regulation of
myoblast proliferation. In contrast, re-introduction of the non-
phosphorylatable SA-Brg1 mutant to Brg1-deleted myoblasts
rescued the proliferation phenotype to the same extent asWT-
Brg1. This result suggests that the inability of these sites to be
phosphorylated has no impact on the ability of Brg1 to promote
myoblast proliferation and viability. However, pharmacological
inhibition of CK2 activity increased myoblast proliferation,
suggesting that critical target residues for CK2 remain func-
tional in the SA mutant and, more importantly, that there is a
dynamic balance between the deposition and removal of phos-
phate groups onBrg1. Pharmacological inhibition ofCK2 activ-
ity increased the rate of myoblast proliferation, although mim-
icking constitutive phosphorylation blocked proliferation and
cell viability. A balance between phosphorylation and dephos-
phorylation is likely a necessity.
One possibility is that the relative level of Brg1 phosphoryla-
tion by CK2 is regulated based on the enzyme function to be
performed. For example, phosphorylation state could deter-
mine whether the enzyme remodels chromatin or engages or
releases from chromatin or from interacting regulatory factors.
The findings about DPF3 phosphorylation discussed above
provide support for such a role. An alternative explanation is
that Brg1 phosphorylation by CK2 is a transitory event during
proliferation. Brg1 is hyperphosphorylated during mitosis and
disengages from the condensing chromatin; SWI/SNF enzymes
purified frommitotic cells are deficient for in vitroATP-depen-
dent nucleosome remodeling activity (62, 63). In this scenario,
CK2-mediated phosphorylation would be necessary for the
inactivation of the mammalian SWI/SNF complex, all because
of the myoblasts to undergo mitosis. As suggested by our data
and as further discussed below, a third possibility is that
dynamic regulation of Brg1 phosphorylation could be used to
control interactions between different SWI/SNF subunits and
therefore as a regulator of the assembly and diversity of SWI/
SNF enzyme complexes. None of these possibilities is mutually
exclusive.
Regardless of the exact nature of CK2’s contribution to Brg1
function, it is manifested in control of Pax7 gene expression.
Pax7 is a master transcriptional regulator for the proliferative
state of the muscle stem cell pool (15, 31–39, 42). Pax7 is
required for the maintenance of the satellite cell population, as
Pax7 knock-out mice have a decreased number of muscle sat-
ellite cells and fail to regenerate muscle (37–39). Our studies in
proliferating primary myoblasts have shown that Pax7 regula-
tion is driven by Brg1 (15). Deletion of Brg1 leads to a decrease
in the expression of Pax7 due to a failure of chromatin remod-
eling at the Pax7 promoter region (15). ChIP and REAA pre-
sented here suggest that the interaction of Brg1 with the Pax7
promoter relies on its phosphorylation state. The non-phos-
phorylatable SA-Brg1 mutant interacted with the Pax7 pro-
moter in a manner similar to the WT-Brg1, but chromatin
interaction and remodeling were abolished when SE-Brg1 was
expressed. The extent of the decrease in Pax7 binding, in chro-
matin remodeling at the Pax7 promoter, and in expression of
Pax7 mRNA due to expression of the SE-Brg1 mutant was
equivalent to that observed in cells completely deleted for Brg1,
suggesting that a cell expressing a Brg1 molecule that mimics
constitutive phosphorylation by CK2 is equivalent to a nullizy-
gous cell. Because introduction of Pax7 into Brg1 null cells res-
cued viability and proliferation (15), the primary function of
Brg1 in myoblasts is to regulate Pax7. It is likely, however, that
a comprehensive analysis of gene expression in primary myo-
blasts expressing theWT-, SA-, and SE-Brg1 will identify other
Brg1 target genes and will improve understanding of additional
downstream consequences of CK2-dependent phosphoryla-
tion during myoblast proliferation.
In addition to effects on Pax7 gene expression, CK2 impacts
Pax7 protein stability. Pax7 levels decrease rapidly upon the
induction of myoblast differentiation. Activation of the caspase
3 protease contributes to Pax7 degradation via targeted cleav-
age of Pax7 (64, 65). This process is impacted by CK2, which
phosphorylates Pax7 in the vicinity of the caspase 3 cleavage site
andsterically inhibitscaspase3activity (64,66,67).CK2phosphor-
ylation of Pax7 therefore promotes myoblast proliferation as well
as satellite cell renewal. Although mimicking constitutive phos-
phorylationofBrg1 through the expressionof the SE-Brg1mutant
is deleterious to myoblast survival, we suggest that appropriate
regulation of Brg1 phosphorylation likely supports myoblast dif-
CK2-dependent phosphorylation regulates Brg1 activity
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ferentiation, raising the possibility that CK2-mediated phosphor-
ylation of Brg1 promotes Pax7 expression, while its simultaneous
phosphorylationofPax7promotesPax7protein stability, reinforc-
ing the proliferative state in myoblasts.
Molecular consequences of Brg1mutation and CK2 inhibition,
changes in sub-nuclear localization and alterations in SWI/
SNF enzyme complex composition
To assess the binding of Brg1 in nuclear complexes in live
cells and changes in binding due to Brg1 mutations that
mimicked or prevented phosphorylation, we performed FRAP
experiments of YFP fused to WT-, SA-, and SE-Brg1. Photo-
bleaching experiments showed significantly decreased initial
binding and a smaller fraction of tightly bound phosphomi-
metic SE-Brg1 compared with WT-Brg1. Subnuclear fraction-
ation showed that endogenous myoblast Brg1, as well as the
ectopically expressed WT-Brg1, were associated with both the
nuclear matrix and chromatin, consistent with previous obser-
vations (48, 49). The SE-Brg1 mutant, however, was associated
with neither. This is consistent with the absence of an immobile
fraction of the SE-Brg1molecule seen in live cells by FRAP; it is
not anchored by any sub-nuclear structure. Interestingly, the
SA-Brg1 mutant showed an immobile fraction that was similar
to that of the WT-Brg1 but an initial recovery that was similar
to that of the SE-Brg1 mutant. The SA-Brg1 protein associated
with the nuclear matrix, but its interaction with chromatin was
greatly decreased. Yet myoblasts expressing the SA-Brg1 sup-
ported proliferation and cell viability, and SA-Brg1 could be
localized to the Pax7 promoter by ChIP. This indicates that
Brg1 association with the nuclear matrix is sufficient for func-
tion and also indicates that the Pax7 promoter is associated
with or in close proximity to the nuclear matrix. Prior studies
looking at specific genes have generally linked matrix-associ-
ated DNA with active transcription (68–70), and the only
genome-wide approach to date showed that matrix-associated
DNAwas enriched in actively expressing genes in immortalized
but non-tumorigenic cells, although it was enriched in non-
expressed genes in a cancer cell line (71). Thus our observations
are consistent with the limited amount of information that
exists on this subject. The biophysical reasons for the altered
binding of the SA- and the SE-Brg1 mutants in live cells as
measured by FRAP remain to be determined. Contributing fac-
tors likely include the number of different complexes in which
Brg1 can bind, the fraction of Brg1 in each complex, the binding
constants for those interactions, and the association of those
complexes with the different forms of chromatin created by
epigeneticmodifications andwith sub-structures of the nuclear
matrix.
Because the SE-Brg1 mutant was detected in the high-salt
wash fraction, associated with neither the chromatin nor the
matrix, and was functionally equivalent to a complete loss of
Brg1, we speculated that the interactions between the SE-Brg1
and other subunits of the SWI/SNF complex may be compro-
mised or absent. Many mammalian SWI/SNF subunits are
encoded by genes that encode highly similar proteins and/or
generate different proteins due to alternative splicing. Some
subunits are mutually exclusive or co-dependent on other sub-
units for inclusion in the complex. The diversity of subunit
composition suggests a high degree of specialization in enzyme
complex function (7, 8). An example is utilization of the Baf170
andBaf155 subunits. Inmouse ESCs, the Baf155 subunit is pref-
erentially expressed and incorporated into BRG1-based SWI/
SNF complexes, whereas ESC differentiation into the neuronal
lineage leads to down-regulation of Baf155, induction of
Baf170, and preferential incorporation of Baf170 into Brg1-
based SWI/SNF enzyme complexes (58). Assessment of Brg1
interactions with Baf155 and Baf170 showed that endogenous
and WT-Brg1 preferentially interacted with Baf170, whereas
the SE mutant interacted poorly but measurably with the
Baf170 protein. The non-phosphorylatable SA mutant and the
endogenous Brg1 from cells treated with CK2 inhibitor prefer-
entially interacted with Baf155. We propose that CK2-medi-
ated phosphorylation of Brg1 contributes to and perhaps drives
the regulation of the subunit composition of the SWI/SNF
complex and, consequently, its function.
Signaling tomammalian SWI/SNF enzyme as a regulatory
mechanism controllingmyogenesis
Priorwork has identified the Baf60c subunit as a substrate for
the p38MAPK. Phosphorylation of BAF60c by p38 at a specific
threonine facilitates assembly of SWI/SNF enzyme atmyogenic
promoters and is required for myogenic differentiation (14).
Phosphorylation of Brg1 at amino acids N- and C-terminal to
the bromodomain by PKC1 prevents Brg1 from binding to or
remodeling chromatin and is therefore refractory to myogenic
gene expression and differentiation. Dephosphorylation by cal-
cineurin counteracts PKC1 activity and removes these phos-
phate groups, activating Brg1 and the SWI/SNF enzyme func-
tion (9). Therefore, there are at least two signaling pathways
converging on SWI/SNF enzymes that modulate their function
and controlmyogenic differentiation.Here,wehave addedCK2
to the list of kinases thatmodify SWI/SNF subunits. In contrast,
however, our evidence suggests that CK2-mediated phosphor-
ylation affects the proliferation of myoblasts and does so by
controlling sub-nuclear localization and the composition of
subunits present in the enzyme complex. Thus, we have estab-
lished that regulation of SWI/SNF enzyme by phosphorylation
includes both the proliferation as well as the differentiation
phase of myogenesis. Given the large number of subunits and
the complexity of SWI/SNF enzyme composition, we suspect
that additional kinases and phosphatases also impact SWI/SNF
function inmyogenesis and that regulation by phosphorylation
is a general principle for controlling SWI/SNF enzyme compo-
sition and function in all cell types.
Experimental procedures
Bioinformatic analyses
Brg1 sequence was analyzed for putative CK2 phosphoryla-
tion sites using the open source NetPhosK program (9, 20).
Plasmid preparation
The full-length human wild-type Brg1 (WT-Brg1) was
cloned into pCR3.1 (Thermo Fisher Scientific) (9). Ten putative
CK2 phosphorylation sites in Brg1 were mutated to alanine
(non-phosphorylatable, SA-Brg1) or glutamate (phosphomi-
CK2-dependent phosphorylation regulates Brg1 activity
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metic, SE-Brg1) using the QuikChange Lightning Multisite-di-
rected mutagenesis kit (Agilent) and primers listed in Table 1.
Mutations were verified by sequencing. The wild-type and
mutant Brg1 sequences were fused to YFP by isolating the
NheI–BamHI fragment from EYFP-c1–Brg1 (72) (kind gift of
Dr. G. Hager, National Institutes of Health), which contains
YFP fused to the N terminus of Brg1, and that fragment was
cloned into AgeI–BamHI-digested pCR3.1-Brg1 for wild type
and each mutant Brg1 sequence. The inducible pBabe LoxP-
mCherry vector was previously described (9). This vector was
digested with AgeI and PmeI as was the pCR3.1-YFP-Brg1, and
the YFPWT-, SA-, and SE-Brg1 fragments were ligated to cre-
ate retroviral vectors encoding the three BRG1 alleles. GST-
Brg1 truncated fusions were reported previously (9).
Primary cell culture
Micewere housed in the animal care facility at theUniversity
of Massachusetts Medical School (Worcester, MA) in accord-
ance with the Institutional Animal Care and Use Committee
guidelines. Mouse satellite cells were purified from whole-leg
muscle from 3- to 6-week-old male and female wild-type
C57Bl/6 or Brg1 conditional mice (41) by differential plating
following Percoll sedimentation as described previously (73).
Muscle tissue was excised, rinsed with Hanks’ balanced salt
solution (HBSS; Thermo Fisher Scientific), sliced into small
pieces, and incubatedwith 0.1%Pronase inHBSS at 37 °C for 60
min. The cell suspension was filtered through a 100-m cell
sieve and resuspended in 3 ml of growth media (GM) contain-
ing a 1:1mix ofDMEMandF-10media, 20% fetal bovine serum,
2% chick embryo extract (Sera Laboratories), and 25 ng/ml
recombinant basic FGF (Millipore). Cells were filtered using a
40-mcell sieve and centrifuged at 1,000 g for 1min at room
temperature. The cells were placed in the top of a Percoll gra-
dient consisting of 35% Percoll layered on top of 70% Percoll
and centrifuged 20 min at 1,850 g at room temperature. The
myoblasts were obtained from the interface of the 70% Percoll
fraction. Cells were washed with HBSS, centrifuged 5 min at
1,000  g, and resuspended and plated in GM. Isolated myo-
blasts were grown on plates coated with 0.02% collagen
(Advanced BioMatrix). Primary myoblasts were plated at 4 
104 cells/cm2 in GM for further analysis. Where indicated, pri-
mary myoblasts obtained from C57Bl/6 mice were incubated
with increasing concentrations (1–10 M) of TBB.
Virus production and primarymyoblast transduction
WT-, SA-, SE-Brg1 retroviruses were produced as described
previously (74). Briefly, 10 g of DNA for each construct were
transfected into Bosc23 cells (75) using Lipofectamine 2000
(Thermo Fisher Scientific). The viral supernatant was collected
after 48 h and filtered through a 0.45-m syringe filter (Milli-
pore). Primary myoblasts were infected with retrovirus in the
presence of 8 g/ml Polybrene and selected for 2 days with 1
g/ml puromycin (Thermo Fisher Scientific). Surviving cells
were then plated in GM at 4  104 cells/cm2. Adenovirus
Table 1
Primers used in this study
F is forward; R is reverse.
Primer name Sequence 5–3 Use
Pax7 LM1 F GAGATCTGAATTCCTGCGCCTTGC REAA
Pax7 LM1 R GATCGAGGGGAGGAGGGAGTCC REAA
Pax7 LM2 F CCGGGAGATCTGAATTCCTGGGTAAG REAA
Pax7 LM2 R TCCCCTCTCCCTCCCGAACTGG REAA
Pax7 LM3 F CCGGGAGATCTGAATTCCTGGAGCAA REAA
Pax7 LM3 R CTCTTTCTTGAACCCAGATAGCCTGCC REAA
Pax7 LM4 F CCGGGAGATCTGAATTCCTGAGGGTG REAA
Pax7 LM4 R GGCTGGACAGGATCTTCA REAA
qPax7 F GCAGCTGGAGGAGCTAGAGAAG Gene expression
qPax7 R GTCTCCTGGCTTGATGGAGTCG Gene expression
qEF1 F AGCTTCTCTGACTACCCTCCACTT Gene expression
qEF1 R GACCGTTCTTCCACCACTGATT Gene expression
qCK2 F GATCAGTTGGTGAGGATAGCCAAGG Gene expression
qCK2 R GGAGTGTCTGCCCAAGATATCGTTG Gene expression
qCK2 F GACCAGCTTGTTCGAATTGCCA Gene expression
qCK2 R CCAGCGCTTCCGTGAATGTTG Gene expression
qCK2 F ATGGACGTGTACACACCCAAGTC Gene expression
qCK2 R ACCATAGAGCCTGGGTACAAACTG Gene expression
qBAF155 F GACTGGTGGTGCAGCTTCTACAGT Gene expression
qBAF155 R GATCCATTCGGGATGGGTTCTGAA Gene expression
qBAF170 F TTGCAGCTGCCTACAAATTCAA Gene expression
qBAF170 R ACAGGATACACAACATGGGAGG Gene expression
Pax7 A ChIP F GTGGCGACAAGGAAGTTCAAACAAAC ChIP
Pax7 A ChIP R AAAGAAAGCCACTCCGCAACCTCTG ChIP
S613A GACCAGCCAGATGGCCGACCTCCCGGTG SA-Brg1 mutation
S695A/S699A CCAGATCCAGACGCCGATGACGTCGCTGAGGTGGACG SA-Brg1 mutation
S1380A/S1382A AAGGAGGTGGACTACGCCGACGCACTGACGGAGAAGC SA-Brg1 mutation
S1570A CGAGAAGGAGGATGACGCTGAAGGCGAGGAGGCT SA-Brg1 mutation
S1575A CAGTGAAGGCGAGGAGGCTGAGGAGGAGGAAGAG SA-Brg1 mutation
S1586A GCGAGGAGGAAGGCGCCGAATCCGAATCT SA-Brg1 mutation
S1627A/S1631A CCAAGCCGGTCGTGGCTGACGATGACGCTGAGGAGGAACAAG SA-Brg1 mutation
S613E GACCAGCCAGATGGAAGACCTCCCGGTG SE-Brg1 mutation
S695E/S699E CCAGATCCAGACGAAGATGACGTCGAAGAGGTGGACG SE-Brg1 mutation
S1380E/S1382E CACCGCAAGGAGGTGGACTACGAGGACGAGCTGACGGAGAAGCAGTGGCTC SE-Brg1 mutation
S1570E AATCGAGAAGGAGGATGACGAGGAAGGCGAGGAG SE-Brg1 mutation
S1575E GAAGGCGAGGAGGAGGAGGAGGAGGAAGAGGG SE-Brg1 mutation
S1586E GGGCGAGGAGGAAGGCGAGGAATCCGAATCTCGGT SE-Brg1 mutation
S1627E/S1631E CGAGCCAAGCCGGTCGTCGAGGACGATGACGAGGAGGAGGAACAAGAGGAG SE-Brg1 mutation
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expressing Cre-recombinase (Ad5CMVCre; Ad-Cre) or con-
taining the empty vector (Ad5CMVempty; negative control)
were used at a multiplicity of infection of 50 and were obtained
fromUniversity of IowaGene Transfer Vector Core. After 48 h,
transduced cells were re-plated at a density of 4 104 cells/cm2
in normal GM, and Brg1 expression was evaluated for 4 days to
determine the times when expression of the exogenous WT-,
SA-, and SE-Brg1 mutants could be observed. Day three was
chosen for further experimentation, consistent with prior work
showing this was the time point at which the endogenous Brg1
was deleted (15).
Primarymyoblast proliferation assays
Primary myoblasts derived from satellite cells from the Brg1
c/c mutant mouse were transduced as indicated above to
induce the expression of the WT-, SA-, and the SE-Brg1
mutants. Three days later, the cells were plated at a density of
1  104 cells/cm2 in normal GM. Where indicated, wild-type
C57Bl/6 were cultured with increasing concentrations of (1–10
M) TBB (Cayman Chemicals). Samples were trypsinized at 24,
48, 72, and 96 h and counted in a Cell-O-Meter (Nexcelom).
Student’s t tests (two-tailed) were performed using Graphpad
Prism Version 7 software.
Protein expression and purification
WT-, SA-, and SE-Brg1 mutant proteins were expressed in
vitro using TNT Quick Coupled Transcription/Translation
Systems (Promega) following the manufacturer’s instructions.
Briefly, 1 g of DNAwas incubated with 40 l of TNTmaster
mix and 1l of 1 mM unlabeledmethionine for 90min at 30 °C.
The resulting Brg1 proteins were immunoprecipitated using a
polyclonal rabbit antisera against Brg1 (40) and PurePro-
teomeTMproteinA/Gmixmagnetic beads (Millipore). Samples
were eluted in buffer containing 50 mM Tris-HCl, pH 7.5, 150
mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, and
Complete Protease Inhibitor Mixture (Roche Diagnostics). In
vitro translatedWT-, SA-, and SE-Brg1 proteins were analyzed
byWestern blotting using the polyclonal rabbit antisera against
Brg1 (40). GST-Brg1 fragments (9) were produced in BL-21
cells following the autoinducing media protocol (76). For pro-
tein expression, cells were grown overnight at 37 °C in 2-YT
medium supplemented with 100 g/ml ampicillin. Bacterial
pellets were sonicated; cell debris was removed by centrifuga-
tion, and the soluble fraction was incubated in a rotating mixer
for 1 h at 4 °C with GST-agarose beads (Pierce) supplemented
with Complete Protease Inhibitors. Samples were washed with
PBS and eluted with 20 mM reduced glutathione (Sigma) in 50
mMTris, pH 8.1. Expression of the GST-Brg1 proteins was ver-
ified by Coomassie Brilliant Blue Staining.
Phosphorylation assays
Forty micrograms of purified WT-, SA-, SE-Brg1 and GST-
Brg1 truncated proteins were incubated for 30 min at 30 °C
with 50 units of CK2 (New England Biolabs) in 1 CK2 Reac-
tion Buffer (20mMTris-HCl, 50mMKCl, 10mMMgCl2, pH 7.5)
and supplemented with 200 M ATP and -labeled ATP
(PerkinElmer Life Sciences) to a final specific activity of 100
Ci/mol. Where noted, TBB was added at the indicated con-
centrations. Then the reactions were separated by SDS-PAGE,
transferred to PVDF membrane, exposed to a phosphorimager
plate, and scanned using a Typhoon laser imager (Molecular
Dynamics). Three (Fig. 1) or four (Fig. 4) independent experi-
ments were performed and analyzed. Phosphorimages were
quantified using ImageJ software, and the phosphorimage sig-
nal was normalized to either Brg1 or GST signal obtained from
a parallel Western blotting.
Antibodies
The antibodies used included the polyclonal rabbit antisera
against Brg1 thatwas previously described (40). The rabbit anti-
casein kinase II (H-286), mouse anti-casein kinase II (D-7),
mouse anti-casein kinase II (6D5), goat anti-Pax-3/7 antibody
(N-19), rabbit anti-caspase-3 antibody (H-277), rabbit anti-
Baf155 antibody (H-76), rabbit anti-Baf170 antibody (H-116),
rabbit anti-lamin 1 (H-90), rabbit anti-pol II (N-20), and rab-
bit anti-MyoD (C-20) were purchased from Santa Cruz Bio-
technology, Inc. Rabbit anti-PI3Kp85 antibody,N-SH2domain
(ABS233) was obtained from Millipore Corp. Mouse anti-
GAPDH-peroxidase-conjugated (G9295) was obtained from
Sigma. Anti-myosin heavy chain (MF20, deposited by D. A.
Fischman) antibody was obtained as a hybridoma supernatant
from the Developmental Studies Hybridoma Bank (University
of Iowa). Donkey anti-rabbit Alexa-488 (A21206) fluorescent
secondary antibody was purchased from Thermo Fisher Scien-
tific. Secondary antibodies anti-mouse and anti-rabbit HRP-
coupled secondary antibodies were obtained from Pierce.
Western blot analysis
Proliferating primary myoblasts were washed with PBS and
solubilized with RIPA buffer (10 mM PIPES, pH 7.4, 150 mM
NaCl, 2 mM EDTA, 1% Triton X-100, 0.5% sodium deoxy-
cholate, and 10% glycerol) containing Complete Protease
Inhibitor Mixture. Forty micrograms of each sample were pre-
pared for SDS-PAGE by boiling in Laemmli buffer. The
resolved proteinswere electrotransferred to a PVDFmembrane
(Bio-Rad). The proteins of interest were detected with the
specific polyclonal or monoclonal antibodies indicated, fol-
lowed by species-appropriate peroxidase-conjugated anti-
bodies (Pierce) and chemiluminescent detection (ECL PLUS;
GE Healthcare). All Western blotting experiments were per-
formed using samples from three independent experiments.
Immunocytochemistry
Cells were grown on 12-well plates and differentiated by
serum depletion (2% horse serum) for 48 h. Cells were fixed
with PBS containing 10% formalin and then incubated over-
night with anti-myosin heavy chain (MF20) antibody (1:100
dilution) alongwith 5% horse serum, 0.2%TritonX-100 in PBS.
Secondary antibody binding and HRP staining were performed
with the ABC universal kit and peroxidase substrate kit Vector
VIP, respectively (Vector Laboratories), according to the man-
ufacturer’s protocol.
Primarymyoblast FRAP analysis
Cells were grown on glass bottom CELLviewTM Advanced
TC culture dishes (Grenier Bio One) for 72 h in growth media.
CK2-dependent phosphorylation regulates Brg1 activity
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FRAP was performed with a Leica TCS SP5 II AOBS confocal
laser-scanning microscope (Leica) using a 63 1.4 n.a. oil
immersion objective. FRAP images of the nucleus of live cells
were scanned before, during, and after photobleaching at 2-s
intervals at 515 nm. To photobleach YFP, maximal laser power
was applied to a region of interest for 1 s. Leica Confocal soft-
ware (LAS AF Lite) was used to measure the intensity of fluo-
rescence in the bleached area, a non-bleached area, and the
whole nucleus for the whole stack of images. The relative fluo-
rescence intensity in the bleach zone was calculated according
to Quaresma et al. (77) with normalization setting the pre-
bleach intensity to 1 and the initial post-bleach intensity to
zero. In this way, a true immobile fraction representing tightly
bound complexes not exchanging over the time course of the
experiment could be calculated. Data were analyzed and plot-
ted usingGraphpad PrismVersion 7. Individual time points are
presented as means with error bars showing standard errors of
the mean. Half-times of recovery and immobile fractions were
calculated by a best fit of each recovery data set to the equation
F(t) Fmax (1 ekt).
Immunoprecipitation
Cells were washed three times with ice-cold PBS and resus-
pended in lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl,
1% Nonidet P-40, 0.5% sodium deoxycholate, and Complete
Protease Inhibitor Mixture). 250 g of cell extract were incu-
bated in a rotating mixer for 2 h with the primary antibody at
4 °C, followed by an overnight incubation with PurePro-
teomeTMProteinA/Gmixmagnetic beads (Millipore). Samples
were washed as indicated by the manufacturer, and immuno-
precipitated proteins were eluted with freshly prepared IP
buffer (10% glycerol, 50mMTris-HCl, pH 6.8, and 1 MNaCl) by
incubating at room temperature for 1 h on a rotating mixer.
Samples were analyzed by SDS-PAGE and Western blotting.
Gene expression analysis
RNA was purified from three independent biological repli-
cates of proliferating primary myoblasts with TRIzol (Thermo
Fisher Scientific). cDNA synthesis was performed with 1 g of
RNA as template, random primers, and SuperScript III reverse
transcriptase (Thermo Fisher Scientific) following the manufa-
cturer’s protocol. Quantitative RT-PCR was performed with
Fast SYBRGreenmaster mix (Thermo Fisher Scientific) on the
ABI StepOnePlus SequenceDetection System (Applied Biosys-
tems) using the primers listed in Table 1 and normalized to the
levels of EF1- expression. Two-tailed t tests were performed
for statistical analyses using Graphpad Prism Version 7.
Chromatin immunoprecipitation assays
ChIP assays using cultured mouse primary myoblasts were
performed in triplicate from independent biological samples as
described previously (15, 78, 79). Lysates fromproliferating pri-
mary myoblasts were incubated overnight with polyclonal rab-
bit antisera against Brg1 (40), rabbit anti-Baf155 (H-76), rabbit
anti-Baf170 (H-116), or normal rabbit IgG (SantaCruzBiotech-
nology). Cross-linking was reversed, and DNA was purified
using ChIP DNA Clean and Concentrator Columns (Zymo
Research). Quantitative PCR was performed using Fast SYBR
Green master mix on the ABI StepOne Plus Sequence Detec-
tion System. Primers used are listed in Table 1. Quantification
was done using the comparative Ct method to obtain the per-
cent of total input DNA pulled down by each antibody (80).
Student’s t tests (two-tailed) were performed using Graphpad
Prism Version 7.
Restriction enzyme accessibility assay
Nuclei from three independent biological replicates of pro-
liferating primary myoblasts derived from mouse satellite cells
were isolated by sucrose gradients. Briefly, the cells were
trypsinized, resuspended in buffer containing 10 mM HEPES,
pH 7.9, 10 mM KCl, 1.5 mM MgCl2, 0.5 mM DTT and homoge-
nized with a Dounce tissue homogenizer. Nuclei were sepa-
rated from cytoplasm by centrifuging the samples 5 min at
218 g at 4 °C, resuspended in 3ml of Buffer S1 (0.25M sucrose,
10 mM MgCl2), then layered over 3 ml of Buffer S2 (0.35 M
sucrose, 10 mM MgCl2), and centrifuged 5 min at 1,430  g at
4 °C. Restriction enzyme accessibility assays were performed as
described previously (81) using primers described in Table 1.
Student’s t tests (two-tailed) were performed using Graphpad
Prism Version 7.
Nuclear fractionation
Nuclear fractionation was performed following the high-salt
isolation protocol previously described (48, 52). Primary myo-
blasts werewashedwith ice-cold PBS and extracted in cytoskel-
eton buffer (CSK: 10 mM PIPES, pH 6.8, 100 mMNaCl, 300 mM
sucrose, 3 mM MgCl2, 1 mM EGTA, 1 mM DTT, and 0.5% (v/v)
Triton X-100 and Complete Protease Inhibitor Mixture). The
cytoskeletal fraction was separated from soluble proteins by
centrifugation at 5,000  g for 3 min. Chromatin was solubi-
lized byDNase I digestion (1 unit, NewEnglandBiolabs) inCSK
buffer plus protease inhibitors for 15 min at 37 °C. Then 0.25 M
(NH4)2SO4 was added, and the samples were incubated for 5
min at 4 °C and centrifuged at 5,000  g for 3 min. The pellet
was washed with 2 M NaCl in CSK buffer for 5 min at 4 °C and
then centrifuged. The remaining pellet containing the nuclear
matrix was solubilized in 8 M urea buffer. Fractions were ana-
lyzed by SDS-PAGE and Western blotting.
Author contributions—T. P.-B., B. T. N., and A. N. I. designed the
experiments. T. P.-B., B. T. N., A. L. P., D. T. H., and J. M. S. per-
formed the experiments. T. P.-B., B. T. N., A. L. P., D. T. H., J. A. N.,
and A. N. I. interpreted the data. T. P.-B., J. A. N., and A. N. I. wrote
the manuscript with assistance and review by the other coauthors.
Acknowledgments—We thank Drs. Yu-Jie Hu and Rasim Barutcu for
useful discussions and suggestions. We thank the Imbalzano labora-
torymembers for comments on themanuscript. TheMF20 hybridoma
media were obtained from the Developmental Studies Hybridoma
Bank, created by the NICHD of the National Institutes of Health and
maintained at the Dept. of Biology, University of Iowa.
References
1. Clapier, C. R., and Cairns, B. R. (2009) The biology of chromatin remod-
eling complexes. Annu. Rev. Biochem. 78, 273–304
2. Flaus, A., and Owen-Hughes, T. (2011) Mechanisms for ATP-dependent
chromatin remodelling: the means to the end. FEBS J. 278, 3579–3595
CK2-dependent phosphorylation regulates Brg1 activity
J. Biol. Chem. (2017) 292(45) 18592–18607 18605
 at U
niversity of M
assachusetts M
edical Center/The Lam
ar Soutter Library on D
ecem
ber 8, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
3. Tyagi,M., Imam,N., Verma, K., and Patel, A. K. (2016) Chromatin remod-
elers: we are the drivers! Nucleus 7, 388–404
4. Khavari, P. A., Peterson, C. L., Tamkun, J.W.,Mendel, D. B., andCrabtree,
G. R. (1993) BRG1 contains a conserved domain of the SWI2/SNF2 family
necessary for normal mitotic growth and transcription. Nature 366,
170–174
5. Muchardt, C., and Yaniv, M. (1993) A human homolog of Saccharomyces
cerevisiae Snf2/Swi2 and Drosophila-Brm genes potentiates transcrip-
tional activation by the glucocorticoid receptor. EMBO J. 12, 4279–4290
6. Wang, W., Côté, J., Xue, Y., Zhou, S., Khavari, P. A., Biggar, S. R., Mucha-
rdt, C., Kalpana, G. V., Goff, S. P., Yaniv,M.,Workman, J. L., andCrabtree,
G. R. (1996) Purification and biochemical heterogeneity of the mamma-
lian SWI-SNF complex. EMBO J. 15, 5370–5382
7. Wu, J. I. (2012) Diverse functions of ATP-dependent chromatin remod-
eling complexes in development and cancer. Acta Biochim. Biophys. Sin.
44, 54–69
8. Hargreaves, D. C., and Crabtree, G. R. (2011) ATP-dependent chromatin
remodeling: genetics, genomics and mechanisms. Cell Res. 21, 396–420
9. Nasipak, B. T., Padilla-Benavides, T., Green, K. M., Leszyk, J. D., Mao,W.,
Konda, S., Sif, S., Shaffer, S. A., Ohkawa, Y., and Imbalzano, A. N. (2015)
Opposing calcium-dependent signalling pathways control skeletal muscle
differentiation by regulating a chromatin remodelling enzyme.Nat. Com-
mun. 6, 7441
10. Simone, C., Forcales, S. V., Hill, D. A., Imbalzano, A. N., Latella, L., and
Puri, P. L. (2004) p38 pathway targets SWI-SNF chromatin-remodeling
complex to muscle-specific loci. Nat. Genet. 36, 738–743
11. Cui, H., Schlesinger, J., Schoenhals, S., Tönjes, M., Dunkel, I., Meierhofer,
D., Cano, E., Schulz, K., Berger, M. F., Haack, T., Abdelilah-Seyfried, S.,
Bulyk, M. L., Sauer, S., and Sperling, S. R. (2016) Phosphorylation of the
chromatin remodeling factor DPF3a induces cardiac hypertrophy
through releasing HEY repressors from DNA. Nucleic Acids Res. 44,
2538–2553
12. Bourachot, B., Yaniv, M., and Muchardt, C. (2003) Growth inhibition by
themammalian SWI-SNF subunit Brm is regulated by acetylation. EMBO
J. 22, 6505–6515
13. Wang, L., Zhao, Z., Meyer,M. B., Saha, S., Yu,M., Guo, A.,Wisinski, K. B.,
Huang, W., Cai, W., Pike, J. W., Yuan, M., Ahlquist, P., and Xu, W. (2014)
CARM1methylates chromatin remodeling factor BAF155 to enhance tu-
mor progression and metastasis. Cancer Cell 25, 21–36
14. Forcales, S. V., Albini, S., Giordani, L., Malecova, B., Cignolo, L., Chernov,
A., Coutinho, P., Saccone, V., Consalvi, S., Williams, R., Wang, K., Wu, Z.,
Baranovskaya, S., Miller, A., Dilworth, F. J., and Puri, P. L. (2012) Signal-
dependent incorporation of MyoD-BAF60c into Brg1-based SWI/SNF
chromatin-remodelling complex. EMBO J. 31, 301–316
15. Padilla-Benavides, T., Nasipak, B. T., and Imbalzano, A. N. (2015) Brg1
controls the expression of Pax7 to promote viability and proliferation of
mouse primary myoblasts. J. Cell. Physiol. 230, 2990–2997
16. de la Serna, I. L., Carlson, K. A., and Imbalzano, A. N. (2001) Mammalian
SWI/SNF complexes promote MyoD-mediated muscle differentiation.
Nat. Genet. 27, 187–190
17. Wang, Y.,Wong, R. H., Tang, T., Hudak, C. S., Yang, D., Duncan, R. E., and
Sul, H. S. (2013) Phosphorylation and recruitment of BAF60c in chroma-
tin remodeling for lipogenesis in response to insulin. Mol. Cell 49,
283–297
18. Kimura, A., Arakawa, N., and Hirano, H. (2014) Mass spectrometric anal-
ysis of the phosphorylation levels of the SWI/SNF chromatin remodeling/
tumor suppressor proteins ARID1A and Brg1 in ovarian clear cell adeno-
carcinoma cell lines. J. Proteome Res. 13, 4959–4969
19. Kwon, S. J., Park, J. H., Park, E. J., Lee, S. A., Lee, H. S., Kang, S. W., and
Kwon, J. (2015) ATM-mediated phosphorylation of the chromatin-re-
modeling enzyme BRG1modulates DNA double-strand break repair.On-
cogene 34, 303–313
20. Blom, N., Sicheritz-Pontén, T., Gupta, R., Gammeltoft, S., and Brunak, S.
(2004) Prediction of post-translational glycosylation and phosphorylation
of proteins from the amino acid sequence. Proteomics 4, 1633–1649
21. Meggio, F., and Pinna, L. A. (2003) One-thousand-and-one substrates of
protein kinase CK2? FASEB J. 17, 349–368
22. Litchfield, D.W. (2003) Protein kinase CK2: structure, regulation and role
in cellular decisions of life and death. Biochem. J. 369, 1–15
23. Seldin, D. C., Lou, D. Y., Toselli, P., Landesman-Bollag, E., and Domin-
guez, I. (2008) Gene targeting of CK2 catalytic subunits. Mol. Cell.
Biochem. 316, 141–147
24. Lou, D. Y., Dominguez, I., Toselli, P., Landesman-Bollag, E., O’Brien, C.,
and Seldin, D. C. (2008) The  catalytic subunit of protein kinase CK2 is
required for mouse embryonic development.Mol. Cell. Biol. 28, 131–139
25. Buchou, T., Vernet, M., Blond, O., Jensen, H. H., Pointu, H., Olsen, B. B.,
Cochet, C., Issinger, O. G., and Boldyreff, B. (2003) Disruption of the
regulatory  subunit of protein kinase CK2 in mice leads to a cell-auton-
omous defect and early embryonic lethality.Mol. Cell. Biol. 23, 908–915
26. Pepperkok, R., Lorenz, P., Jakobi, R., Ansorge, W., and Pyerin, W. (1991)
Cell-growth stimulation by Egf- inhibition through antisense-oligodeoxy-
nucleotides demonstrates important role of casein kinase-Ii. Exp. Cell Res.
197, 245–253
27. Lorenz, P., Pepperkok, R., Ansorge,W., and Pyerin,W. (1993) Cell biolog-
ical studies with monoclonal and polyclonal antibodies against human
Casein kinase-Ii subunit- demonstrate participation of the kinase in mi-
togenic signaling. J. Biol. Chem. 268, 2733–2739
28. Pepperkok, R., Lorenz, P., Ansorge, W., and Pyerin, W. (1994) Casein
kinase-Ii is required for transition of G(0)/G(1), early G(1), and G(1)/S
phases of the cell-cycle. J. Biol. Chem. 269, 6986–6991
29. Mauro, A. (1961) Satellite cell of skeletal muscle fibers. J. Biophys.
Biochem. Cytol. 9, 493–495
30. Dumont, N. A., Bentzinger, C. F., Sincennes, M. C., and Rudnicki, M. A.
(2015) Satellite cells and skeletal muscle regeneration. Compr. Physiol. 5,
1027–1059
31. Motohashi, N., and Asakura, A. (2014) Muscle satellite cell heterogeneity
and self-renewal. Front. Cell Dev. Biol. 2, 1
32. Montarras, D., L’honoré, A., and Buckingham, M. (2013) Lying low but
ready for action: the quiescent muscle satellite cell. FEBS J. 280,
4036–4050
33. Brack, A. S., and Rando, T. A. (2012) Tissue-specific stem cells: lessons
from the skeletal muscle satellite cell. Cell Stem Cell 10, 504–514
34. Chang, N. C., and Rudnicki, M. A. (2014) Satellite cells: the architects of
skeletal muscle. Curr. Top. Dev. Biol. 107, 161–181
35. Sambasivan, R., and Tajbakhsh, S. (2015) Adult skeletal muscle stem cells.
Results Probl. Cell Differ. 56, 191–213
36. Mansouri, A., Stoykova, A., Torres, M., and Gruss, P. (1996) Dysgenesis of
cephalic neural crest derivatives in Pax7/ mutant mice. Development
122, 831–838
37. Seale, P., Sabourin, L. A., Girgis-Gabardo, A., Mansouri, A., Gruss, P., and
Rudnicki, M. A. (2000) Pax7 is required for the specification of myogenic
satellite cells. Cell 102, 777–786
38. Oustanina, S., Hause, G., and Braun, T. (2004) Pax7 directs postnatal re-
newal and propagation of myogenic satellite cells but not their specifica-
tion. EMBO J. 23, 3430–3439
39. Relaix, F., Montarras, D., Zaffran, S., Gayraud-Morel, B., Rocancourt, D.,
Tajbakhsh, S., Mansouri, A., Cumano, A., and Buckingham, M. (2006)
Pax3 and Pax7 have distinct and overlapping functions in adult muscle
progenitor cells. J. Cell Biol. 172, 91–102
40. de La Serna, I. L., Carlson, K. A., Hill, D. A., Guidi, C. J., Stephenson, R. O.,
Sif, S., Kingston, R. E., and Imbalzano, A. N. (2000)Mammalian SWI-SNF
complexes contribute to activation of the hsp70 gene.Mol. Cell. Biol. 20,
2839–2851
41. Bultman, S., Gebuhr, T., Yee, D., La Mantia, C., Nicholson, J., Gilliam, A.,
Randazzo, F., Metzger, D., Chambon, P., Crabtree, G., and Magnuson, T.
(2000) A Brg1 null mutation in the mouse reveals functional differences
among mammalian SWI/SNF complexes.Mol. Cell 6, 1287–1295
42. Zammit, P. S., Relaix, F., Nagata, Y., Ruiz, A. P., Collins, C. A., Partridge,
T. A., and Beauchamp, J. R. (2006) Pax7 and myogenic progression in
skeletal muscle satellite cells. J. Cell Sci. 119, 1824–1832
43. Porter, A. G., and Jänicke, R. U. (1999) Emerging roles of caspase-3 in
apoptosis. Cell Death Differ. 6, 99–104
44. Sarno, S., Reddy,H.,Meggio, F., Ruzzene,M., Davies, S. P., Donella-Deana,
A., Shugar, D., and Pinna, L. A. (2001) Selectivity of 4,5,6,7-tetrabromo-
CK2-dependent phosphorylation regulates Brg1 activity
18606 J. Biol. Chem. (2017) 292(45) 18592–18607
 at U
niversity of M
assachusetts M
edical Center/The Lam
ar Soutter Library on D
ecem
ber 8, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
benzotriazole, an ATP site-directed inhibitor of protein kinase CK2 (‘ca-
sein kinase-2’). FEBS Lett. 496, 44–48
45. Ruzzene, M., Penzo, D., and Pinna, L. A. (2002) Protein kinase CK2 inhib-
itor 4,5,6,7-tetrabromobenzotriazole (TBB) induces apoptosis and
caspase-dependent degradation of haematopoietic lineage cell-specific
protein 1 (HS1) in Jurkat cells. Biochem. J. 364, 41–47
46. Nickerson, J. A. (2009) The biochemistry of RNA metabolism studied in
situ. RNA Biol. 6, 25–30
47. Kruhlak,M. J., Lever,M.A., Fischle,W., Verdin, E., Bazett-Jones, D. P., and
Hendzel, M. J. (2000) Reduced mobility of the alternate splicing factor
(ASF) through the nucleoplasm and steady state speckle compartments.
J. Cell Biol. 150, 41–51
48. Reyes, J. C., Muchardt, C., and Yaniv, M. (1997) Components of the hu-
man SWI/SNF complex are enriched in active chromatin and are associ-
ated with the nuclear matrix. J. Cell Biol. 137, 263–274
49. Zhao, K., Wang, W., Rando, O. J., Xue, Y., Swiderek, K., Kuo, A., and
Crabtree, G. R. (1998) Rapid and phosphoinositol-dependent binding of
the SWI/SNF-like BAF complex to chromatin after T lymphocyte recep-
tor signaling. Cell 95, 625–636
50. Fawcett, D. W. (1966) An Atlas of Fine Structure: The Cell, Its Organelles
and Inclusions.W. B. Saunders Co., Philadelphia
51. Vogelstein, B., Pardoll, D. M., and Coffey, D. S. (1980) Supercoiled loops
and eukaryotic DNA replication. Cell 22, 79–85
52. He, D. C., Nickerson, J. A., and Penman, S. (1990) Core filaments of the
nuclear matrix. J. Cell Biol. 110, 569–580
53. Dahmus, M. E. (1981) Purification and properties of calf thymus casein
kinases I and II. J. Biol. Chem. 256, 3319–3325
54. Cabrejos, M. E., Allende, C. C., andMaldonado, E. (2004) Effects of phos-
phorylation by protein kinase CK2 on the human basal components of the
RNA polymerase II transcription machinery. J. Cell. Biochem. 93, 2–10
55. Tripodi, F., Nicastro, R., Busnelli, S., Cirulli, C., Maffioli, E., Tedeschi, G.,
Alberghina, L., and Coccetti, P. (2013) Protein kinase CK2 holoenzyme
promotes start-specific transcription in Saccharomyces cerevisiae. Eu-
karyot. Cell 12, 1271–1280
56. Trembley, J. H., Hu, D., Slaughter, C. A., Lahti, J. M., and Kidd, V. J. (2003)
Casein kinase 2 interacts with cyclin-dependent kinase 11 (CDK11) in vivo
and phosphorylates both the RNA polymerase II carboxyl-terminal do-
main and CDK11 in vitro. J. Biol. Chem. 278, 2265–2270
57. Wang, W., Xue, Y., Zhou, S., Kuo, A., Cairns, B. R., and Crabtree, G. R.
(1996) Diversity and specialization of mammalian SWI/SNF complexes.
Genes Dev. 10, 2117–2130
58. Ho, L., Ronan, J. L., Wu, J., Staahl, B. T., Chen, L., Kuo, A., Lessard, J.,
Nesvizhskii, A. I., Ranish, J., andCrabtree, G. R. (2009)An embryonic stem
cell chromatin remodeling complex, esBAF, is essential for embryonic
stem cell self-renewal and pluripotency. Proc. Natl. Acad. Sci. U.S.A. 106,
5181–5186
59. Meggio, F., Marin, O., and Pinna, L. A. (1994) Substrate-specificity of
protein-kinase Ck2. Cell. Mol. Biol. Res. 40, 401–409
60. Meek, D. W., Simon, S., Kikkawa, U., and Eckhart, W. (1990) The P53
tumor suppressor protein is phosphorylated at serine-389 by casein ki-
nase-Ii. EMBO J. 9, 3253–3260
61. Bouazoune, K., and Brehm, A. (2005) dMi-2 chromatin binding and re-
modeling activities are regulated by dCK2 phosphorylation. J. Biol. Chem.
280, 41912–41920
62. Muchardt, C., Reyes, J. C., Bourachot, B., Leguoy, E., and Yaniv, M. (1996)
The hbrmandBRG-1 proteins, components of the humanSNF/SWI com-
plex, are phosphorylated and excluded from the condensed chromosomes
during mitosis. EMBO J. 15, 3394–3402
63. Sif, S., Stukenberg, P. T., Kirschner, M. W., and Kingston, R. E. (1998)
Mitotic inactivation of a human SWI/SNF chromatin remodeling com-
plex. Genes Dev. 12, 2842–2851
64. Dick, S. A., Chang, N. C., Dumont, N. A., Bell, R. A., Putinski, C., Kawabe,
Y., Litchfield, D. W., Rudnicki, M. A., and Megeney, L. A. (2015) Caspase
3 cleavage of Pax7 inhibits self-renewal of satellite cells. Proc. Natl. Acad.
Sci. U.S.A. 112, E5246–E5252
65. Olguín, H. C. (2011) Regulation of Pax7 protein levels by caspase-3 and
proteasome activity in differentiating myoblasts. Biol. Res. 44, 323–327
66. Duncan, J. S., Turowec, J. P., Duncan, K. E., Vilk, G.,Wu,C., Lüscher, B., Li,
S. S., Gloor, G. B., and Litchfield, D. W. (2011) A peptide-based target
screen implicates the protein kinase CK2 in the global regulation of
caspase signaling. Sci. Signal. 4, ra30
67. González, N., Moresco, J. J., Cabezas, F., de la Vega, E., Bustos, F., Yates,
J. R., 3rd, Olguín, H. C. (2016) Ck2-dependent phosphorylation is required
to maintain Pax7 protein levels in proliferating muscle progenitors. PLoS
One 11, e0154919
68. Gerdes, M. G., Carter, K. C., Moen, P. T., Jr, and Lawrence, J. B. (1994)
Dynamic changes in the higher-level chromatin organization of specific
sequences revealed by in situ hybridization to nuclear halos. J. Cell Biol.
126, 289–304
69. Maya-Mendoza, A., Hernández-Muñoz, R., Gariglio, P., and Aranda-An-
zaldo, A. (2003) Gene positional changes relative to the nuclear substruc-
ture correlate with the proliferating status of hepatocytes during liver
regeneration. Nucleic Acids Res. 31, 6168–6179
70. Maya-Mendoza, A., and Aranda-Anzaldo, A. (2003) Positional mapping
of specific DNA sequences relative to the nuclear substructure by direct
polymerase chain reaction on nuclear matrix-bound templates. Anal.
Biochem. 313, 196–207
71. Dobson, J. R., Hong, D., Barutcu, A. R., Wu, H., Imbalzano, A. N., Lian,
J. B., Stein, J. L., van Wijnen, A. J., Nickerson, J. A., and Stein, G. S. (2017)
Identifying nuclear matrix-attached DNA across the genome. J. Cell.
Physiol. 232, 1295–1305
72. Johnson, T. A., Elbi, C., Parekh, B. S., Hager, G. L., and John, S. (2008)
Chromatin remodeling complexes interact dynamically with a glucocor-
ticoid receptor-regulated promoter.Mol. Biol. Cell 19, 3308–3322
73. Bischoff, R., and Heintz, C. (1994) Enhancement of skeletal muscle regen-
eration. Dev. Dyn. 201, 41–54
74. Morgenstern, J. P., and Land, H. (1990) Advancedmammalian gene trans-
fer: high titre retroviral vectors with multiple drug selection markers and
a complementary helper-free packaging cell line. Nucleic Acids Res. 18,
3587–3596
75. Pear,W. S., Nolan, G. P., Scott,M. L., and Baltimore, D. (1993) Production
of high-titer helper-free retroviruses by transient transfection. Proc. Natl.
Acad. Sci. U.S.A. 90, 8392–8396
76. Studier, F.W. (2005) Protein production by auto-induction in high density
shaking cultures. Protein Expr. Purif. 41, 207–234
77. Quaresma, A. J., Sievert, R., and Nickerson, J. A. (2013) Regulation of
mRNA export by the PI3 kinase/AKT signal transduction pathway. Mol.
Biol. Cell 24, 1208–1221
78. Dacwag, C. S., Ohkawa, Y., Pal, S., Sif, S., and Imbalzano, A. N. (2007) The
protein arginine methyltransferase Prmt5 is required for myogenesis be-
cause it facilitates ATP-dependent chromatin remodeling.Mol. Cell. Biol.
27, 384–394
79. Hernández-Hernández, J.M.,Mallappa, C., Nasipak, B. T., Oesterreich, S.,
and Imbalzano, A. N. (2013) The Scaffold attachment factor b1 (Safb1)
regulates myogenic differentiation by facilitating the transition of myo-
genic gene chromatin from a repressed to an activated state.Nucleic Acids
Res. 41, 5704–5716
80. Livak, K. J., and Schmittgen, T. D. (2001) Analysis of relative gene expres-
sion data using real-time quantitative PCR and the 2(C(T)) Method.
Methods 25, 402–408
81. Ohkawa, Y., Mallappa, C., Vallaster, C. S., and Imbalzano, A. N. (2012) An
improved restriction enzyme accessibility assay for analyzing changes in
chromatin structure in samples of limited cell number.MethodsMol. Biol.
798, 531–542
CK2-dependent phosphorylation regulates Brg1 activity
J. Biol. Chem. (2017) 292(45) 18592–18607 18607
 at U
niversity of M
assachusetts M
edical Center/The Lam
ar Soutter Library on D
ecem
ber 8, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Haokip, Jake M. Schnabl, Jeffrey A. Nickerson and Anthony N. Imbalzano
Teresita Padilla-Benavides, Brian T. Nasipak, Amanda L. Paskavitz, Dominic T.
myoblast proliferation and contributes to SWI/SNF complex composition
Casein kinase 2-mediated phosphorylation of Brahma-related gene 1 controls
doi: 10.1074/jbc.M117.799676 originally published online September 22, 2017
2017, 292:18592-18607.J. Biol. Chem. 
  
 10.1074/jbc.M117.799676Access the most updated version of this article at doi: 
 Alerts: 
  
 When a correction for this article is posted•  
 When this article is cited•  
 to choose from all of JBC's e-mail alertsClick here
  
 http://www.jbc.org/content/292/45/18592.full.html#ref-list-1
This article cites 80 references, 32 of which can be accessed free at
 at U
niversity of M
assachusetts M
edical Center/The Lam
ar Soutter Library on D
ecem
ber 8, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
